Product
CARCIK-CD19
2 clinical trials
4 indications
Indication
B-cell non-Hodgkin lymphomaIndication
Chronic Lymphocytic LeukemiaIndication
Acute Lymphoblastic LeukemiaIndication
RelapseClinical trial
Phase I/II Trial to Determine the in Vivo Engraftment, Safety and Clinical Activity of Allogeneic CIK Cells Transduced With a Transposon CD19-chimeric Antigen Receptor (CARCIK-CD19) Gene in Adult and Pediatric Patients With Relapsed/Refractory B-cell Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
Phase 1-2a Trial to Determine the Feasibility and Safety of a Single Dose of Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Adult and Pediatric Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, After Hematopoietic Stem Cell TransplantationStatus: Completed, Estimated PCD: 2021-03-31